James H.  Stanker net worth and biography

James Stanker Biography and Net Worth

Mr. Stanker was appointed as our Chief Financial Officer effective September 5, 2018. Mr. Stanker has over 30 years of financial and executive leadership experience in the areas of accounting principles and audit standards, regulatory reporting, and fiscal management and strategy. He has served in a financial leadership role as an audit partner at Grant Thornton from February 2000 until his retirement in August 2016. His responsibilities included managing the audit quality in the Atlantic Coast Market Territory. From 2009 to 2012, he served as the Global Head of Audit Quality for Grant Thornton International. Prior to joining Grant Thornton, Mr. Stanker served as the Chief Financial Officer for a NASDAQ listed company and for a privately-held life science company. Mr. Stanker is a Certified Public Accountant. He has a bachelor's degree in Aeronautics from San Jose State University and a Master's in Business Administration from California State University, East Bay. He currently serves on the Board of Directors and is Chairman of the Audit Committee of GSE Systems, Inc. Mr. Stanker is also an adjunct professor in the George B. Delaplaine School of Business at Hood College. Since his retirement from Grant Thornton, Mr. Stanker has provided financial consulting services to numerous companies.

How old is James H. Stanker?

Mr. Stanker is currently 66 years old. There are 5 older executives and no younger executives at Processa Pharmaceuticals. The oldest executive at Processa Pharmaceuticals is Dr. David Young Ph.D., Pharm.D., Co-Founder, President of Research and Development & Director, who is 71 years old. Learn More on James H. Stanker's age.

How do I contact James H. Stanker?

The corporate mailing address for Mr. Stanker and other Processa Pharmaceuticals executives is 7380 COCA COLA DRIVE SUITE 106, HANOVER MD, 21076. Processa Pharmaceuticals can also be reached via phone at (443) 776-3133 and via email at [email protected]. Learn More on James H. Stanker's contact information.

Has James H. Stanker been buying or selling shares of Processa Pharmaceuticals?

James H. Stanker has not been actively trading shares of Processa Pharmaceuticals over the course of the past ninety days. Learn More on James H. Stanker's trading history.

Who are Processa Pharmaceuticals' active insiders?

Processa Pharmaceuticals' insider roster includes Robert Floyd (COO), Patrick Lin (Insider), James Stanker (CFO), Justin Yorke (Director), and David Young (CEO). Learn More on Processa Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Processa Pharmaceuticals?

During the last year, Processa Pharmaceuticals insiders bought shares 4 times. They purchased a total of 41,500 shares worth more than $105,895.00. The most recent insider tranaction occured on February, 7th when insider David Young bought 21,000 shares worth more than $51,450.00. Insiders at Processa Pharmaceuticals own 13.0% of the company. Learn More about insider trades at Processa Pharmaceuticals.

Information on this page was last updated on 2/7/2024.

James H. Stanker Insider Trading History at Processa Pharmaceuticals

See Full Table

James H. Stanker Buying and Selling Activity at Processa Pharmaceuticals

This chart shows James H. Stanker's buying and selling at Processa Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Processa Pharmaceuticals Company Overview

Processa Pharmaceuticals logo
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.
Read More

Today's Range

Now: $0.90
Low: $0.90
High: $0.92

50 Day Range

MA: $1.25
Low: $0.90
High: $1.44

2 Week Range

Now: $0.90
Low: $0.85
High: $17.40

Volume

5,357 shs

Average Volume

1,133,612 shs

Market Capitalization

$2.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6